$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong execution
to ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10
$Trillium Therapeutics(TRIL)$operating planis on track. Focus is on strong execution
to ensure a robust flow of new data starting in 4Q 2021 and 2022. Holding $265m cash position. Trillium’s position as a leading CD47 company makes it a buy at $6.10
Comments